In early March, Back Bay wrote an article suggesting that an intensely challenging period was coming, as indicated by multiple factors and an upswing in market volatility.
Read MoreIn part one of a two-part series, published this week in Cell & Gene, Back Bay Life Science Advisors explores the evolution of cell therapies of the innate immune system (such as γδ T and NK cells) to understand why these approaches offer great hope for oncology and the potential value they may offer second-generation cell therapy companies.
Read MoreCodexis Signs Strategic Collaboration and License Agreement with Takeda to Advance Novel Gene Therapies for Rare Genetic Disorders
Read MoreEconomic shocks, elections, geopolitical events, oil price wars, COVID-19, and the impact of public health issues on travel and markets, have jarred the record-setting ten-year equities bull market into a period of gut-wrenching volatility and price corrections.
Read MoreSTAT
Biotech innovations dominate the life science news cycle — think CRISPR for gene editing or CAR-T for cancer immunotherapy. Medical technologies, encompassing the broad swath of devices and interventional technologies, diagnostics, imaging, and digital medicine, tend to make their marks out of the limelight, yet have an enormous impact on public health and offer significant investment opportunities.
Read MoreBack Bay Life Science Advisors is proud to have served as exclusive strategic and financial advisors to Centrexion Therapeutics in the licensing agreement of its non-opioid pain asset to Eli Lilly and Company (NYSE: LLY).
Read MoreFor decades, the time-consuming and vastly expensive nature of drug discovery has been a significant pain point for pharmaceutical and biotech companies, who continually seek new technologies to improve the process.
Read MoreAs healthcare evolves to become more patient-centric, the FDA has expressed increasing interest in the use of patient-reported outcomes (PROs) as endpoints in clinical trials. A PRO is any report, directly from the patient, that provides information on the status of the patient’s health, disease burden, medication usage, and other experiences.
Read MoreOn Friday, June 29 Amazon announced that it would be acquiring its first online pharmacy retailer, PillPack for $1 billion in cash. With around $100 million in revenue last year, the acquisition price implies a 9x – 10x revenue multiple for the Company.
Read MoreBack Bay Life Science Advisors, the leading integrated strategy and investment banking firm for global life science companies and investors, announces the ongoing expansion of our strategy consulting team.
Read More